Glenn Flux

Royal Marsden Hospital
Head of radioisotope physics

Dr Glenn Flux is Head of Radioisotope Physics at the Royal Marsden Hospital and Institute of Cancer Research in Sutton, UK. His main research focus is on translational quantitative SPECT and PET imaging and its application to internal dosimetry for molecular radiotherapy. He has been involved in the development of imaging and dosimetry for clinical procedures including I-131 mIBG treatment of neuroblastoma and the treatment and palliation of bone metastases from prostate cancer with Re-186 HEDP and Ra-223. He has published over 100 peer reviewed articles and received research funding from national and international bodies. He is a founder member of the EANM Dosimetry Committee and is currently chair of the British Nuclear Medicine Society Molecular Radiotherapy committee.

dont miss

The emergence and resurgence of radiotherapeutics for cancer treatment

Cancer treatment with radiopharmaceuticals is growing rapidly with many new radiotherapeutics either in development or early phase trials. Molecular radiotherapy and theragnostics promise to offer significant advances in cancer care and the market is expected to grow by 30% per annum for the foreseeable future. This presentation will review the potential impact of this expansion for industry, academia, and patient benefit.

EVEN MORE SEMINARS

  • Sanjay Prabhu, MBBS: Speaking at the European Neurological Convention

    Sanjay Prabhu, MBBS
    Harvard Medical School / Boston Children’s Hospital

    3D printing, virtual surgery and mixed reality in the OR - fad or trend?

  • Dr Youssef Mentias: Speaking at the European Neurological Convention

    Dr Youssef Mentias
    City Hospitals Sunderland NHS Foundation Trust

    Review of Hypopharyngeal and Laryngeal pathology

  • Estevao Mauricio Bagi: Speaking at the European Neurological Convention

    Estevao Mauricio Bagi
    Royal Brompton & Harefield Hospitals Specialist Care

    Cardiac PET-CT : Rubidium-82 Myocardium Perfusion & 18F-FDG Cardiac Sarcoidosis

  • Dr John Buscombe: Speaking at the European Neurological Convention

    Dr John Buscombe
    British Nuclear Medicine Society

    Theranostics in prostate cancer new or false dawn

  • Professor David Maintz: Speaking at the European Neurological Convention

    Professor David Maintz
    University Hospital Cologne, Department of Radiology

    Spectral CT: Dual layer technology helps to increase diagnostic confidence